Highlights {#S1}
==========

1.  Recombinase-based isothermal amplification assays (RPA/RAA) were specific and sensitive, with the detection limits of 93.4 and 53.6 copies per reaction at 95% probability in 16 min.

2.  Both RPA and RAA present good agreement with OIE real-time PCR for the detection of African swine fever virus (ASFV) with clinical samples.

3.  These methods, coupled with field-deployable platform, provide an easy, reliable, sensitive and specific tool for the rapid diagnosis of ASFV, particularly screening and surveillance for the early detection.

Introduction {#S2}
============

African swine fever (ASF), as a notifiable disease to the World Organization for Animal Health (OIE), is a highly contagious, viral pig disease caused by African swine fever virus (ASFV). ASFV has been currently classified to the genus *Asfivirus* of the family *Asfarviridae*. The genome of this large, complex double-stranded DNA virus (170--193 kbp) consists of 151--167 genes ([@B15]). So far, 24 different genotypes and 8 serogroups have been identified based on ASFV *B646L* gene (encoding the capsid protein p72) and *EP402R* gene (encoding the serotype-specific protein CD2v), respectively ([@B2]; [@B28], [@B29]). ASF infection of domestic pigs and wild boars causes high fever, lethargy, digestive dysfunction, respiratory discharges, nasal discharges and abortion, with the mortality close to 100%. The diverse transmission modes include a sylvatic cycle between swine and arthropod vector (*Ornithodoros moubata* ticks), direct or indirect contact between susceptible animal and infected pigs, contaminated secretions (blood, feces, urine, mucus) or fomites (vehicles, equipment) ([@B12]). To date, no effective vaccine or antiviral treatment has been developed, while the quarantine, depopulation and sanitation strategies remain the routine ways to control the spread of ASF.

African swine fever belongs to a transboundary animal disease. Since it was first described in Kenya in 1921 ([@B31]), ASFV has been found in other 25 African countries ([@B32]). In the 1950s, ASF incursions were subsequently reported in European countries, including Portugal, Spain, France, Italy, Belgium, the Netherlands, Malta and the virus further spread to the Caribbean and South America (Brazil, Cuba, Haiti, Dominican Republic) ([@B13]). Except for Sardinia, Madagascar and sub-Saharan African countries, all of the outbreaks were eradicated in the mid 1990s. In 2007, ASF was first reported in Georgia and continued its spread to the Trans-Caucasus region, parts of the Russian Federation and Eastern Europe, which has already affected Russia, Ukraine, Belarus, Azerbaijan, Armenia, Poland, Latvia, Lithuania, Estonia, Moldova, Czech Republic, Hungary, Bulgaria, Romania and Belgium through large geographic jumps ([@B34]). In August 2018, ASF outbreak in China was first reported ([@B17]; [@B43]), and the infections later occurred in other Asian countries, including Mongolia, Viet Nam, Cambodia, Democratic People's Republic of Korea, Lao People's Democratic Republic, Myanmar, The Philippines, Republic of Korea, Timor-Leste, Indonesia, Papua New Guinea, India^[1](#footnote1){ref-type="fn"}^. The disease poses a serious threat and high hazard to the swine industry and food security worldwide.

Polymerase chain reaction (PCR)-based diagnostic methods have been commonly applied for the detection of ASFV with high sensitivity and specificity, including conventional PCR and real-time PCR. Basically, its complex procedures consist of three steps, denaturation, annealing and extension, in multiple cycles, which require highly specialized equipment. However, they are costly, time-consuming and inappropriate for wide application in resource-limited laboratories or even in the field. Isothermal amplification has recently been introduced for the detection of various viruses ([@B9]; [@B21]; [@B36]). The detection of ASFV with loop-mediated isothermal amplification (LAMP), for instance, shows concordance with real-time PCR but requires four or more primers, and primer design is typically complex ([@B22]; [@B41]). The development of alternative, recombinase-based isothermal amplification, i.e., recombinase polymerase amplification (RPA) developed by TwistDx (Cambridge, United Kingdom) ([@B26]), or recombinase-aided amplification (RAA) by Qitian (Wuxi, China) ([@B35]), advance nucleic acid-based tests as rapid, specific, diversified readout, and avoid the use of comprehensive thermal cyclers. It employs the recombinase and its cofactor to bind with oligonucleotide primers in search for homologous DNA. However, as the critical component in RPA, uvsX is the recombinase of T4 phage while the recombinant enzyme of RAA is obtained from *E. coli*, which can closely bind to primer DNA at room temperature. The strands then exchange after the recognition and single strand binding (SSB) protein combines with the parental strand to continue the amplification with template strand. DNA polymerase launches the template synthesis from 3′ --terminal of primers for the form of new duplex DNA. In this way, specific fragment is exponentially amplified as the cycle is repeated ([@B33]) ([Figure 1A](#F1){ref-type="fig"}).

![Schematic of recombinased-based assay and process of sampling, nucleic acid extraction and amplification. **(A)** Recombinased-based reaction mechanism. **(B)** Probe principle. **(C)** Whole process of recombinased-based (RPA/RAA) detection.](fmicb-11-01696-g001){#F1}

Recombinase-based isothermal amplification is conducted at 37--42°C. The detectable amplification signal requires 10--20 min and can be detected by gel electrophoresis, real-time monitoring, or visualizing with lateral flow dipstick (LFD). The real-time detection incorporates a fluorogenic probe besides forward and reverse primers, and the reaction initiates based on the cleavage of probe at an abasic site \[i.e., tetrahydrofuran (THF) or a dSpacer (a derivative of the THF) or a dR group (the deoxyribose of the abasic site via a C-O-C linker)\] between the fluorophor and the quencher with *E. coli* exonuclease III or glycosylase/lyase ([@B24]) ([Figure 1B](#F1){ref-type="fig"}). The real-time detection has been applied for the rapid diagnosis of several viruses (HIV, hepatitis B virus, coxsackievirus, respiratory syncytial virus, porcine circovirus 2, small ruminant morbillivirus) ([@B10]; [@B39]; [@B6]; [@B26]; [@B35]), bacteria (Salmonella, Clostridium difficile, Escherichia coli, Vibrio parahaemolyticus, Campylobacter jejuni, Actinobacillus pleuropneumoniae) ([@B37]; [@B7]; [@B42]; [@B18]; [@B25]), parasites (Fasciola hepatica) ([@B5]). However, there is a potential risk of aerosol contamination of amplicon during the visual read-out procedure by gel electrophoresis and lateral flow strip ([@B8]; [@B4]). Real-time assay in a relatively close system can perform successfully in both laboratories and open-air environment, which rules out the possible influence of dust from outside and contamination leading to false positive result. Our preliminary data showed a rapid, sensitive, specific diagnostic assay for ASFV by using real-time fluorescent RPA ([@B20]). In this study, we aim to validate the clinical performance of two recombinase-based isothermal amplification methods, RPA, RAA, and further compared those with OIE real-time PCR on the detection of field samples.

Materials and Methods {#S3}
=====================

Recombinant Plasmids and Viruses {#S3.SS1}
--------------------------------

The partial sequence of major capsid protein p72 gene characterized for genotyping from 24 ASFV genotypes (GenBank accession number: [AF302816](AF302816), [AM999764](AM999764), [AF270706](AF270706), [FJ528594](FJ528594), [DQ250120](DQ250120), [AF302818](AF302818), [AY494553](AY494553), [AF270711](AF270711), [AF302818](AF302818), [AF270705](AF270705), [AY351564](AY351564), [AF449463](AF449463), [AY351522](AY351522), [AY351543](AY351543), [AY351542](AY351542), [AY351555](AY351555), [AY494552](AY494552), [AY494551](AY494551), [DQ250119](DQ250119), [DQ250122](DQ250122), [DQ250127](DQ250127), [DQ250109](DQ250109), [DQ250125](DQ250125), [DQ250117](DQ250117), [KT795360](KT795360), [KY353989](KY353989)) were synthesized and inserted into pUC57 plasmid vector (Sangon, Shanghai, China). The concentration of DNA (AM999764) was determined as 8.3 × 10^10^ copies/μL by using Nanodropone (Thermo Fisher Scientific, Waltham, MA, United States). Classical swine fever virus (CSV) (Shimen), Foot-and-mouth virus (FMDV) (MYA98), Pseudorabies virus (Bartha K61), Porcine circovirus 2 (PCV2) (ZJ/C), Porcine reproductive and respiratory syndrome virus (PPRSV) (SDWH) infected samples or porcine genomic DNA were preserved in National Surveillance and Research Center for Exotic Animal Disease.

Clinical Samples {#S3.SS2}
----------------

Clinical samples, including EDTA-blood, spleen, lung, lymph node, kidney, tonsil, liver, brain, were collected from domestic pigs in China. These samples were firstly detected by real-time PCR as OIE recommended ([@B23]) at the National Reference Laboratory for ASF, China Animal Health and Epidemiology Center from September to December, 2018. Based on the result, in this study, a panel of 64 negative and 88 positive samples (including 20 weak positive Ct value ≥ 30) was adopted.

Nucleic Acid Extraction {#S3.SS3}
-----------------------

We employed the TaqMan PCR assay with internal amplification control for the detection of African swine fever virus, along with additional extraction controls before this stage, according to the previous study ([@B23]). First of all, we need to ensure that no problem happened during the extraction process and then OIE-qPCR was conducted. In brief, the total viral DNA was extracted from 200 μL of samples \[EDTA-blood, supernatant tissue homogenates diluted 1:10 in phosphate-buffered saline (PBS, pH 7.4)\] by using Magnetic beads pre-filled viral nucleic acid extraction kit (Tianlong Science and Technology, Xi'an, Shanxi, China) according to the manufacturer's instructions ([@B26]). The total nucleic acid was eluted using dH~2~O water in a final volume of 100 μL and stored at −80°C until further use for all assays in this study.

Real-Time PCR Assay {#S3.SS4}
-------------------

The real-time PCR assay was performed on Light Cycler 480 (Roche, Mannheim, Germany) according to the previous study as OIE recommended ([@B23]). The reactions were prepared as a 20 μL reaction volume containing 10 μL 2× super mix containing enzyme (Takara, Kusatsu, Japan), 0.8 μL forward primers, 0.8 μL reverse primers, 0.4 μL probe and 2 μL extracted DNA. The following thermal program was: reverse transcription at 95°C for 2 min and 40 cycles of amplification (15 s at 94°C and 1 min at 60°C).

ASFV-Specific Primers and Probe for RPA/RAA {#S3.SS5}
-------------------------------------------

The primers and probe applied in RPA/RAA reactions was based on previous report ([@B20]). Forward primer, 5′-TTCCGTAACTGCTCATGGTATCAATCTTATCG-3′; Reverse primer, 5′-GATACCACAAGATCAGCCGTAGTGATAGAC-3′; Probe, 5′-GATACGTTAATATGACCACTGGGTTGGTAT-FAM-C-THF-T-BHQ1-CCGTGGCTTCAAAGC. The primers and probe were synthesized from Sangon (Shanghai, China).

Real-Time RPA/RAA Conditions {#S3.SS6}
----------------------------

Real-time RPA assay was performed in a 50 μL volume using the TwistAmp exo kit (TwistDx, Cambridge, United Kingdom). The reaction mixture included 29.5 μL rehydration buffer, 2 μL extracted DNA template, 2.1 μL forward primer (10 μM), 2.1 μL reverse primer (10 μM), 0.6 μL probe (10 μM), 11.2 μL dH~2~O, and 2.5 μL magnesium acetate (280 mM). Real-time RAA assay was performed in a 50 μL volume using the RAA nucleic acid amplification kit (fluorescence method, F00001) (Qitian, Wuxi, China). The reaction mixture included 25 μL rehydration buffer, 2 μL extracted DNA template, 2.1 μL forward primer (10 μM), 2.1 μL reverse primer (10 μM), 0.6 μL probe (10 μM), 15.7 μL dH~2~O and 2.5 μL magnesium acetate (280 mM). The RPA or RAA reaction mixture was firstly treated in isothermal vibration mixer (RAA-B6100, Qitian, Wuxi, China) at 39°C for 4 min (brief mix, centrifugation, vibration) and then incubated for 16 min at 39°C with real-time fluorometer (RAA-F1620, Qitian, Wuxi, China) to detect fluorescence (FAM) signal every 20 s. The criteria of threshold limit for positive results were determined as described previously ([@B26]).

Analytical Sensitivity and Specificity of Real-Time RPA/RAA {#S3.SS7}
-----------------------------------------------------------

To determine the detection limit of the real-time RPA/RAA, serial dilutions of recombinant plasmids with concentration including 8.3, 41.5, 83, 415, 830, 4150, 8300 copies/μL were prepared. Each concentration was assayed in eight replicates by the real-time RPA/RAA. The analytical specificity of ASFV real-time RPA/RAA was evaluated among other swine pathogens with similar clinical signs (CSV, FMDV, PRV, PCV2, PPRSV and DNA fragments from 24 ASFV genotypes (10^3^ ∼ 10^4^ copies/μL).

Comparison of the Real-Time RPA/RAA Assay With Real-Time PCR Assay Using Clinical Samples {#S3.SS8}
-----------------------------------------------------------------------------------------

To explore the clinical performance of the real-time RPA/RAA assays in the detection of clinical specimen, 152 samples by veterinary service were collected during outbreaks of ASFV from September to December 2018. The performance of real-time RPA/RAA assays was compared to that of real-time PCR assay. The degree of agreement between the real-time RPA/RAA and real-time PCR assay results were measured with kappa value by using MedCalc software (MedCalc Software bvba, Ostend, Belgium).

Statistical Analysis {#S3.SS9}
--------------------

Data in this study were presented as mean ± standard deviation. For the determination of the ASFV real-time RPA/RAA assay analytical sensitivity, a semi-log regression analysis (PRISM, Graphpad Software Inc., San Diego, CA, United States). The probit regression analysis using MedCalc Software (MedCalc Software bvba, Ostend, Belgium) was performed with data of eight replicates from serial dilutions to calculate the detection limit of the real-time RPA/RAA assay at a 95% probability level. At least triplicates were used in the experiment.

Results {#S4}
=======

Sensitivity and Specificity of ASFV Real-Time RPA/RAA {#S4.SS1}
-----------------------------------------------------

We analyzed the sensitivity of ASFV RPA, RAA by detecting ASFV p72 recombinant plasmids at concentrations of 8.3, 41.5, 83, 415, 830, 4150, 8300 copies/μL in eight replicates ([Figures 2A,B](#F2){ref-type="fig"}). Our result regarding probit regression analysis showed that the detection limits of RPA and RAA at 95% probability were 93.4 copies per reaction (56.9 ∼ 619.8 copies per reaction, 95% CI) and 53.6 copies per reaction (30.7 ∼ 241.0 copies per reaction, 95% CI), respectively ([Figures 2C,D](#F2){ref-type="fig"}). We then tested the specificity of RPA/RAA assay as well as determined the detection range of RPA/RAA method on all the genotypes of ASFV. ASFV p72 recombinant plasmids of 24 genotypes at concentration of 10^3^ ∼10^4^ copies/μL, along with CSV, FMDV, PRV, PCV2, PPRSV, were involved in the specificity test. Positive results were found among all genotypes of ASFV, whereas no cross reaction of the other microbes was shown ([Figures 2E,F](#F2){ref-type="fig"}).

![The sensitivity and specificity of recombinased-based amplification. ASFV DNA molecules after series dilution were detected by real-time RPA **(A)** and RAA **(B)** (copies per reaction). Probit regression analysis using MedCalc Software was performed on data of 8 replicates from serial dilutions by real-time RPA **(C)** and RAA **(D)**. Specificity test result of real-time RPA **(E)** and RAA **(F)** on detecting ASFV 24 genotypes, CSV, FMDV, PRV, PCV2, and PPRSV.](fmicb-11-01696-g002){#F2}

Performance of ASFV RPA/RAA Assay on Clinical Samples and Its Comparison With Real-Time PCR Testing {#S4.SS2}
---------------------------------------------------------------------------------------------------

In order to evaluate the practical application of ASFV real-time RPA/RAA, 152 porcine samples of EDTA-blood, spleen, lung, lymph node, kidney, tonsil, liver, brain, suspected for ASFV were tested and the results were compared with that by OIE-recommended real-time PCR. Eighty eight samples were confirmed as ASFV DNA positive (Ct value, ranging from 14.77 to 39.50) while 64 as negative (Ct value, undetermined). By the detection of real-time RPA, 85 samples were identified as ASFV DNA positive \[Threshold time (TT) value, ranging from 3.17 to 16.00\] and 67 as negative (TT value, undetermined) ([Table 1](#T1){ref-type="table"}). Alternatively, the result of real-time RAA indicated 86 positive (TT value, ranging from 1.33 to 15.50) and 66 negative samples (TT value, undetermined). Linear correlation analysis revealed that, during the detection, as the Ct value of real-time PCR increased, the TT value by recombinase-based isothermal amplification present a growing trend correspondingly ([Figure 3](#F3){ref-type="fig"}). Agreement analysis based on the detection of field samples showed that the kappa value between real-time RPA and reference real-time PCR was 0.960 (0.915 ∼ 1, 95% CI), while between real-time RAA and reference real-time PCR was 0.973 (0.936 ∼ 1, 95% CI). Additionally, in comparison to real-time PCR, the specificity and the sensitivity of RPA assay for identification of ASFV were 100% (94.40% ∼ 100%, 95% CI) and 96.59% (90.36% ∼ 99.29%, 95% CI), respectively, while those of RAA were 100% (94.40% ∼ 100%, 95% CI) and 97.73% (92.03% ∼ 99.72%, 95% CI) respectively, indicating an excellent diagnostic agreement between recombinase-based isothermal amplification and real-time PCR ([Table 2](#T2){ref-type="table"}).

###### 

Detection of ASFV by RPA and RAA in clinical samples.

  **Sample ID**   **Sample type**   **qPCR**       **RAA**   **RPA**                            
  --------------- ----------------- -------------- --------- -------------- ---- -------------- ----
  P1              Blood             19.40          \+        7.00           \+   4.00           \+
  P2              Blood             19.60          \+        1.33           \+   5.17           \+
  P3              Blood             19.90          \+        2.00           \+   6.00           \+
  P4              Blood             20.90          \+        7.33           \+   6.33           \+
  P5              Blood             21.30          \+        7.17           \+   9.50           \+
  P6              Blood             21.54          \+        10.50          \+   6.67           \+
  P7              Blood             21.80          \+        4.50           \+   6.33           \+
  P8              Blood             21.80          \+        6.67           \+   7.17           \+
  P9              Blood             21.90          \+        4.67           \+   10.50          \+
  P10             Blood             21.90          \+        3.33           \+   7.67           \+
  P11             Blood             21.90          \+        6.67           \+   8.67           \+
  P12             Blood             22.00          \+        3.33           \+   7.33           \+
  P13             Blood             22.90          \+        10.50          \+   7.33           \+
  P14             Blood             23.50          \+        12.00          \+   9.17           \+
  P15             Blood             29.00          \+        13.33          \+   10.67          \+
  P16             Blood             29.90          \+        14.17          \+   Undetermined   --
  P17             Blood             32.05          \+        8.00           \+   12.00          \+
  P18             Blood             32.40          \+        12.83          \+   7.83           \+
  P19             Blood             33.08          \+        Undetermined   \-   11.50          \+
  P20             Blood             33.08          \+        8.33           \+   10.33          \+
  P21             Blood             33.50          \+        12.83          \+   13.67          \+
  P22             Blood             33.60          \+        11.67          \+   11.50          \+
  P23             Blood             34.50          \+        6.67           \+   11.17          \+
  P24             Blood             35.10          \+        6.83           \+   9.83           \+
  P25             Blood             35.13          \+        10.50          \+   11.83          \+
  P26             Blood             35.20          \+        9.50           \+   16.00          \+
  P27             Blood             35.38          \+        9.33           \+   10.33          \+
  P28             Blood             36.20          \+        12.50          \+   12.67          \+
  P29             Blood             36.70          \+        10.50          \+   9.33           \+
  P30             Blood             36.70          \+        9.50           \+   11.67          \+
  P31             Blood             37.43          \+        9.00           \+   13.17          \+
  P32             Blood             38.50          \+        10.00          \+   12.17          \+
  P33             Blood             39.50          \+        12.67          \+   Undetermined   \-
  P34             Brain             20.56          \+        4.83           \+   4.83           \+
  P35             Brain             22.35          \+        3.00           \+   3.17           \+
  P36             Brain             25.50          \+        6.83           \+   12.83          \+
  P37             Brain             25.70          \+        8.00           \+   9.67           \+
  P38             Brain             26.19          \+        7.33           \+   5.50           \+
  P39             Brain             26.96          \+        7.83           \+   10.83          \+
  P40             Brain             29.93          \+        9.83           \+   11.50          \+
  P41             Brain             35.39          \+        Undetermined   --   13.50          \+
  P42             Brain             36.50          \+        15.50          \+   Undetermined   --
  P43             Brain             36.30          \+        10.67          \+   12.67          \+
  P44             Kidney            22.60          \+        4.00           \+   5.83           \+
  P45             Kidney            23.02          \+        4.50           \+   10.83          \+
  P46             Kidney            18.20          \+        3.33           \+   5.83           \+
  P47             Kidney            19.42          \+        6.00           \+   8.33           \+
  P48             Kidney            21.11          \+        4.50           \+   8.00           \+
  P49             Kidney            21.46          \+        4.67           \+   8.83           \+
  P50             Kidney            21.88          \+        5.83           \+   8.17           \+
  P51             Kidney            22.50          \+        3.00           \+   5.83           \+
  P52             Kidney            23.00          \+        3.50           \+   11.00          \+
  P53             Kidney            23.11          \+        4.83           \+   8.83           \+
  P54             Liver             18.69          \+        8.67           \+   6.83           \+
  P55             Liver             19.40          \+        2.50           \+   6.33           \+
  P56             Liver             19.50          \+        5.67           \+   7.50           \+
  P57             Lung              17.40          \+        4.33           \+   6.33           \+
  P58             Lung              18.75          \+        6.17           \+   9.33           \+
  P59             Lung              19.26          \+        6.17           \+   5.00           \+
  P60             Lung              19.50          \+        5.17           \+   7.33           \+
  P61             Lung              20.30          \+        4.83           \+   11.83          \+
  P62             Lymph node        14.77          \+        3.33           \+   9.00           \+
  P63             Lymph node        15.96          \+        5.50           \+   9.67           \+
  P64             Lymph node        16.91          \+        5.17           \+   8.67           \+
  P65             Lymph node        18.60          \+        3.17           \+   5.00           \+
  P66             Lymph node        18.69          \+        3.83           \+   8.50           \+
  P67             Lymph node        20.13          \+        4.50           \+   8.67           \+
  P68             Lymph node        20.49          \+        4.83           \+   7.67           \+
  P69             Lymph node        21.57          \+        3.83           \+   6.50           \+
  P70             Lymph node        23.11          \+        5.33           \+   9.33           \+
  P71             Lymph node        23.24          \+        5.33           \+   11.33          \+
  P72             Lymph node        24.32          \+        5.50           \+   11.17          \+
  P73             Spleen            15.64          \+        3.17           \+   6.33           \+
  P74             Spleen            16.98          \+        2.83           \+   8.00           \+
  P75             Spleen            17.57          \+        2.83           \+   6.33           \+
  P76             Spleen            18.15          \+        10.17          \+   6.00           \+
  P77             Spleen            18.21          \+        4.00           \+   8.83           \+
  P78             Spleen            18.50          \+        2.83           \+   4.67           \+
  P79             Spleen            18.50          \+        5.83           \+   10.50          \+
  P80             Spleen            18.52          \+        3.33           \+   5.67           \+
  P81             Spleen            18.58          \+        2.83           \+   7.33           \+
  P82             Spleen            18.77          \+        4.17           \+   8.17           \+
  P83             Spleen            18.83          \+        2.33           \+   7.50           \+
  P84             Spleen            18.93          \+        2.50           \+   7.17           \+
  P85             Spleen            19.20          \+        3.83           \+   8.50           \+
  P86             Spleen            19.20          \+        2.33           \+   7.50           \+
  P87             Spleen            19.63          \+        2.67           \+   7.67           \+
  P88             Tonsil            22.99          \+        5.00           \+   7.33           \+
  N1              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N2              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N3              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N4              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N5              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N6              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N7              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N8              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N9              Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N10             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N11             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N12             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N13             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N14             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N15             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N16             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N17             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N18             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N19             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N20             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N21             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N22             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N23             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N24             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N25             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N26             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N27             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N28             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N29             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N30             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N31             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N32             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N33             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N34             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N35             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N36             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N37             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N38             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N39             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N40             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N41             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N42             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N43             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N44             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N45             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N46             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N47             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N48             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N49             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N50             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N51             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N52             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N53             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N54             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N55             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N56             Blood             Undetermined   --        Undetermined   --   Undetermined   --
  N57             Kidney            Undetermined   --        Undetermined   --   Undetermined   --
  N58             Kidney            Undetermined   --        Undetermined   --   Undetermined   --
  N59             Kidney            Undetermined   --        Undetermined   --   Undetermined   --
  N60             Lymph node        Undetermined   --        Undetermined   --   Undetermined   --
  N61             Lymph node        Undetermined   --        Undetermined   --   Undetermined   --
  N62             Spleen            Undetermined   --        Undetermined   --   Undetermined   --
  N63             Spleen            Undetermined   --        Undetermined   --   Undetermined   --
  N64             Spleen            Undetermined   --        Undetermined   --   Undetermined   --

![Comparison of clinical performance between the threshold time of ASFV real-time RPA (*x* axis) **(A)**, RAA (*x* axis) **(B)**, and Ct value of real-time PCR (*y* axis) on positive field samples (*n* = 88).](fmicb-11-01696-g003){#F3}

###### 

Diagnostic performance comparison between RPA/RAA and qPCR assays.

                                                              **qPCR**        **Performance characteristics (%)**                                    
  ------------------------------------------------ ---------- ---------- ---- ------------------------------------- -------------------------------- ----------------------------
  RPA                                              Positive   85         0    85                                    96.59% (90.36%∼99.29%, 95% CI)   100% (94.40%∼100%, 95%CI)
                                                   Negative   3          64   67                                                                     
                                                              88         64   152                                                                    
  Agreement Kappa value: 0.960 (0.915 1, 95% CI)                                                                                                     
  RPA                                              Positive   86         0    86                                    97.73% (92.03%∼99.72%, 95%CI)    100% (94.40%∼100%, 95% CI)
                                                   Negative   2          64   66                                                                     
                                                              88         64   152                                                                    

Agreement Kappa value: 0.973 (0.936∼1, 95%CI).

Discussion {#S5}
==========

African swine fever represents a deadly infectious disease that causes an acute hemorrhagic fever in domestic pigs and wild boars with the mortality rate up to 100%. It currently poses major concern for global swine industry owing to the "second wave" of trans-continents transmission of ASF from Africa to Europe and Asia since 2007 in Georgia after the effective eradication except Africa and the island of Sardinia in late 1990s ([@B12]). Unfortunately, trans-regional transportation of live pigs and pork products, the lack of good farming practice and biosecurity, movements of people and vehicles increase its further spread, which leads to costly socio-economic impact to affected countries. As there are no effective vaccines or antiviral treatment available, early detection and diagnosis at different settings, such as farms, slaughterhouses, are urgently needed as primary measures to control the disease. However, officially approved diagnostic approaches for ASF include virus isolation, fluorescent antibody test (FAT), PCR, real-time PCR, indirect fluorescent antibody (IFA), enzyme-linked immunosorbent assay (ELISA) and immunoblotting test, which generally require expensive laboratory equipment and skilled technicians ([@B11]). This study described a rapid and reliable recombinase-based amplification assay for the detection of ASFV DNA, and evaluated its clinical potential by using two kinds of commercial kits, RPA, RAA.

Recombinase-based isothermal assay (RPA/RAA) emerges as a simple, rapid, specific and sensitive nucleic acid amplification, with the advantage of constant temperature rather than sophisticated thermocycling by PCR or real-time PCR with relatively expensive machine. It particularly assists the external application from advanced laboratories to low-resource settings ([@B14]). It has been shown that, among the development of simple and rapid detection for ASF, LAMP assay can test at least 330 genomic copies in 75 min ([@B22]), polymerase cross-linking spiral reaction (PCLSR) reached 720 copies/μL in 45 min ([@B40], [@B41]), cross-priming amplification (CPA) identified the minimum detection limit as 200 copies within 60 min ([@B16]), chimeric DNA/LNA-based biosensor processed up to 40 samples (one sample at a time, time per analysis = 5 min) with the limits of detection being 178 copies/μL ([@B3]), and pen-side molecular diagnostic UPL assay based on qPCR technique still required at least 35 min ([@B27]). However, recombinase-based assay maintains detection limit of PCR but customarily shortens the reaction time from 45∼120 min of LAMP, PCLSR, CPA, PCR to 10∼30 min, correspondingly. Preliminary recombinase-based isothermal studies showed that the detection limit of ASF DNA was 108 copies per reaction (95% CI, five runs) based on RPA primers and exo probes ([@B38]), while sensitivity was 150 copies per reaction within 15∼20 min in RPA with lateral flow detection (LFD) ([@B30]). Consistently, in our study, by testing eight replicates of serial dilutions, the analytical sensitivity of real-time RPA and RAA was further determined as 93.4 and 53.6 copies per reaction at 95% probability in 16 min, which were in a similar range (magnitude) of sensitivity and present favorable specificity as previously reported. Additionally, we evaluated the versatility on the detection of all 24 genotypes of ASFV. To the best of our knowledge, it is the first work that demonstrates a universal molecular diagnosis on all ASFV genotypes.

Recent evidence revealed that, in comparison between LAMP and CPA, although CPA reached 7.2 copies of standard ASFV plasmid, which was more sensitive than LAMP of 330 copies, yet in case of field performance, the sensitivity of CPA was 70% (14/20), lower than that of LAMP 90% (18/20), suggesting the detective potential between plasmids and clinical samples may vary ([@B41]). In this scenario, we further validate the clinical performance of recombinase-based isothermal amplification assays with 152 various kinds of field samples suspected for ASFV, including EDTA-blood, spleen, lung, lymph node, kidney, tonsil, liver, brain. Our data revealed that the specificity of both recombinased-based assays was 100%, while the sensitivity of RPA or RAA was 96.59 or 97.73%, respectively, suggesting a favorable suitability of recombinased-based assay similar to real-time PCR in clinical practice. Particularly, among 88 positive samples by OIE real-time PCR, there were 20 weak positive (Ct value ≥ 30) and 18 were tested positive by RPA/RAA. The result was also in line with and a recent review on 63 RPA-related literatures describing clinical/field trials that recombinase-based assays present a relatively high clinical specificity (100%, 51/58; 90 ∼ 99%, 5/58) and sensitivity (100%, 32/63; 80 ∼ 99%, 25/63) ([@B24]).

In field-deployable diagnostic studies, it has been shown that Ebola virus disease (EVD) in point-of-care of Guinea primed the assembly containing a mobile glove box and a Diagnostics-in-a-Suitcase powered by a battery and solar panel and yielded a sensitivity and specificity of 100% in comparison with the real-time RT-PCR assay while saved the reaction time ([@B14]). RT-RPA mobile laboratory for Dengue virus 1--4 was established, combined with magnetic bead based total RNA extraction and a portable detection device on centrifugal lab desks that fulfilled the requirements, and all reagents involved in the mobile laboratory were cold-chain independent ([@B1]). The utilization of a light-weight, field-deployable automatic taco^TM^ mini Nucleic Acid Automatic Extraction System, along with the insulated isothermal (ii) PCR/POCKIT^TM^ system provided an on-site diagnosis of patients with MERS-CoV infection within an hour. Notably, the overall kappa values between the two RT-iiPCR assays and the reference RT-qPCR assays were 0.96 and 0.99 ([@B19]). Concomitantly, we described a simple-to-use assay format, which involves magnetic bead-based DNA extraction, pretreatment and recombinase-based isothermal amplification and processes up to 16 samples a time within 45∼50 min ([Figure 1C](#F1){ref-type="fig"}). Our clinical result exhibited that RPA and RAA had good agreement to OIE real-time PCR (kappa value, 0.960, 0.973, respectively) and eased the manipulation of ASF diagnosis potentially for all veterinarians, veterinary officers, even inexperienced farmers in low-resource settings, without extra operation and potential carryout contamination caused by amplicon in opening tubes during result readout of agarose gel or LFD ([@B30]). Although RPA/RAA has not been so far recognized as a confirmatory diagnostic method the same as PCR or qPCR, and still requires extensive validation, it provides a potentially rapid and reliable strategy applied for early diagnosis, which is essential for subsequent early response, including disposal, movement control, disinfection, etc.

Taken together, our data on both experimental and field samples demonstrate that two recombinase-based isothermal amplification assays (RPA/RAA), coupled with field-deployable platform, contribute to a sensitive, specific and reliable tool for rapid detection of ASFV in clinic, which further facilitates screening and surveillance of ASF in the future.
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